Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles
Pharmaceutical Research · 2024-08 · 41 (8) · 1573-1594
DOI: 10.1007/s11095-024-03757-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, online erschienen am 07.08.2024. Verfasst von Yoshinobu Takakura und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. takakura@pharm.kyoto-…. Hauptthemen laut MEDLINE: Extracellular Vesicles, Quality Control. Die Arbeit wurde bisher 187-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PMDA, Japan, Kanazawa University.
Abstract (Originalsprache)
Extracellular vesicles (EVs) serve as an intrinsic system for delivering functional molecules within our body, playing significant roles in diverse physiological phenomena and diseases. Both native and engineered EVs are currently the subject of extensive research as promising therapeutics and drug delivery systems, primarily due to their remarkable attributes, such as targeting capabilities, biocompatibility, and low immunogenicity and mutagenicity. Nevertheless, their clinical application is still a long way off owing to multiple limitations. In this context, the Science Board of the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan has conducted a comprehensive assessment to identify the current issues related to the quality and safety of EV-based therapeutic products. Furthermore, we have presented several examples of the state-of-the-art methodologies employed in EV manufacturing, along with guidelines for critical processes, such as production, purification, characterization, quality evaluation and control, safety assessment, and clinical development and evaluation of EV-based therapeutics. These endeavors aim to facilitate the clinical application of EVs and pave the way for their transformative impact in healthcare.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. takakura@pharm.kyoto-u.ac.jp.
- WPI Nano Life Science Institute (NanoLSI), Kanazawa University, Kanazawa, Japan. hanayama@med.kanazawa-u.ac.jp.
- Department of Polymer Chemistry, Graduate School of Engineering, Kyoto University, Kyoto, Japan.
- Institute for Chemical Research, Kyoto University, Kyoto, Japan.
- Vascular Biology and Molecular Biology, Faculty of Dental Medicine, Hokkaido University, Sapporo, Japan.
- Department of Materials Engineering, School of Engineering, The University of Tokyo, Bunkyō, Japan.
Förderung
- PMDA, Japan
- Kanazawa University
Zitieren
APA
Takakura, Y., Hanayama, R., Akiyoshi, K., Futaki, S., Hida, K., Ichiki, T., Ishii-Watabe, A., Kuroda, M., Maki, K., Miura, Y., Okada, Y., Seo, N., Takeuchi, T., Yamaguchi, T., & Yoshioka, Y. (2024). Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles. Pharmaceutical Research, 41(8), 1573-1594. https://doi.org/10.1007/s11095-024-03757-4
Vancouver
Takakura Y, Hanayama R, Akiyoshi K, Futaki S, Hida K, Ichiki T, et al. Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles. Pharmaceutical Research. 2024;41(8):1573-1594. doi:10.1007/s11095-024-03757-4
BibTeX
@article{Takakura2024,
author = {Takakura, Yoshinobu and Hanayama, Rikinari and Akiyoshi, Kazunari and Futaki, Shiroh and Hida, Kyoko and Ichiki, Takanori and Ishii-Watabe, Akiko and Kuroda, Masahiko and Maki, Kazushige and Miura, Yasuo and Okada, Yoshiaki and Seo, Naohiro and Takeuchi, Toshihide and Yamaguchi, Teruhide and Yoshioka, Yusuke},
title = {Quality and Safety Considerations for Therapeutic Products Based on Extracellular Vesicles},
journal = {Pharmaceutical Research},
year = {2024},
volume = {41},
number = {8},
pages = {1573--1594},
doi = {10.1007/s11095-024-03757-4}
}
EUVIMED